Allen Taylor, MD, thinks AI-powered plaque evaluations can make a substantial impact on patient care. 

Gen Xers and their elders tend to believe AI will do more harm than good. More than half of American adults 50 and older place themselves in that somewhat cynical category. 

AI can hurt or help the cause of advancing equality of resources, services and outcomes in healthcare. If it’s to do more helping than hurting, the technology must permeate primary care—and do so with certain goals and guidelines. 

These specialized, AI-powered cameras can automate and optimize patient positioning based on their body habitus and placement on the table.

Heartflow filed necessary documents for the public offering on Thursday following positive news related to its key software, including proposed coverage under the MPFS. 

Not only could its use reduce wait times, but it also could cut the associated costs of imaging.

Heartflow, known for its AI-based CCTA evaluations, appears to be going public. The news follows years of momentum for the California-based company, including improved Medicare reimbursements for cardiac CT and a new Category I CPT code for its Plaque Analysis software.

One of the study's most significant findings was that patients managed using the advanced AI software saw LDL cholesterol drops of 18.7 mg/dL, with a 15% reduction in their risk of a cardiac event. Even patients with no calcified plaque saw significant changes in care management.